3 hypolipidemic drugs are included in medical insurance, Ge Junbo: so that more patients benefit from blood lipid standards

The Paper's reporter He Liping

Cardiovascular disease is the number one killer that threatens the health of our residents. The results of the adjustment of the 2021 national medical insurance drug list recently announced show that 3 new lipid-lowering drugs, including aliciclimab (boolida ®), have been newly included in the list.

Professor Ge Junbo, academician of the Chinese Academy of Sciences and director of the Department of Cardiology of Zhongshan Hospital affiliated to Fudan University, said, "In recent years, the prevalence of cardiovascular disease in China is still in a continuous upward stage, atherosclerotic cardiovascular disease (ASCVD) is the primary threat to the health of Chinese residents, especially the mortality rate of acute coronary syndrome (ACS) remains high, which is related to the high low-density lipoprotein cholesterol (LDL-C) of patients, so reducing LDL-C is the core of secondary prevention of ACS patients. ”

It is worth noting that at present, the number of cardiovascular disease patients in China has reached 330 million, with an average of about 3.5 million people dying from cardiovascular diseases every year. Atherosclerotic cardiovascular disease is the primary threat to the health of chinese residents, and dyslipidemia is one of the most important risk factors for atherosclerosis.

The data show that the mortality rate of patients with acute myocardial infarction in particular is still increasing year by year, according to long-term follow-up studies of patients, the total incidence of coronary artery events in patients with acute coronary syndrome in 1 year after discharge is 12.5%, and the mortality rate within 2 years is 5.2%. The blood lipid management status of patients with acute coronary syndrome in China is not ideal, the compliance rate is less than 50%, and the risk of recurrence of cardiovascular events is high.

Taking aliciclizumab as an example, Sanofi introduced that alizelixumab not only has evidence-based evidence support for significantly reducing cardiovascular events in patients with acute coronary syndrome, but is also the only PCSK9 inhibitor that has been confirmed to be associated with a 15% reduction in all-cause deaths, and can significantly reduce LDL cholesterol levels by 61% in recent ACS patients who have been treated with statins.

Previously, in December 2019, aliciclizumab was approved for listing in China. Sanofi believes that its advantage of subcutaneous injection every two weeks has brought a new choice for lipid-lowering treatment for Chinese patients, which is easy to use and conducive to improving patient compliance. Aliciyumab is now officially included in the National Health Insurance Catalogue for the prevention of cardiovascular events in adults diagnosed with atherosclerotic cardiovascular disease and for the treatment of reduced LDL cholesterol levels in adults with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia.

Ge Junbo believes that "after aliciclizumab is included in medical insurance, more patients can benefit from blood lipid standards, prevent the recurrence of cardiovascular events in patients, and prolong patients' lives." ”

Dr. Pius S. Hornstein PhD, President of Sanofi Greater China, said, "The successful entry of Aliciyuzumab injection into the 2021 National Health Insurance Catalogue is an important milestone for Sanofi and the majority of patients with cardiovascular risk factors with poor control of cholesterol abnormalities, and it is also a practical embodiment of the country's encouragement of breakthrough innovative product technology. ”

Editor-in-Charge: Li Yuequn Photo Editor: Shi Jiahui

Proofreader: Yan Zhang